TEST CHANGE

Chromogranin A, Serum

3002867, CGA

Specimen Requirements:	
Patient Preparation:	
Collect:	Serum separator tube or plain red.
Specimen Preparation:	Allow serum specimen to clot completely at room temperature. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Transport Temperature:	Frozen.
Unacceptable Conditions:	Plasma.
Remarks:	
Stability:	After separation from cells: Ambient: 48 hours; Refrigerated: 3 days; Frozen: 3 months~~4 weeks~~
Methodology:	Immunofluorescence
Performed:	Sun, Mon, Wed, Fri
Reported:	1-5 days
Note:	
CPT Codes:	86316
New York DOH Approval Status:	This test is New York DOH approved.

Interpretive Data:

This test is performed using the BRAHMS CGA II Kryptor kit. Results obtained with different methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease and should be evaluated in combination with clinical symptoms, diagnostic evidence, and/or other laboratory parameters.

The change ofCgA concentration over time provides diagnostic information whether a tumor progression has occurred.

An increase of CgA serum concentrations of more than 50% to avalue of greater than 100 ng/ml between consecutive monitoring visits defines a positive test result, representing a higher probability that a tumor progression has occurred.

A change of CgA serum concentrations of equal or less than 50% increase between monitoring visits or to a value of 100 ng/ml or less defines a negative test result, representing a lower

probability that a tumor progression has occurred.

Nontumor ~~.~~

~~Nontumor-~~related elevations of Chromogranin A can be observed in gastrointestinal, cardiovascular, and renal disorders, cancers other than neuroendocrine tumors, as well as with proton pump inhibitor (PPI) therapy. It is recommended to stop PPI treatment for at least 14 days prior to testing. ~~two weeks prior to testing. Moderate H2-receptor antagonist therapy does not lead to significant elevations of Chromogranin A.~~

~~This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.~~

Reference Interval:

0-187~~103~~ ng/mL